Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center
Baltimore, Maryland, 21224, United States
NCT Number: NCT02033707
This non-treatment study will investigate the effects on mood and performance caused by hallucinogens and other psychoactive compounds.
Looking for future studies?
Notify Me21 year–50 year
All sexes
Interventional
Phase 1
Baltimore, Maryland, 21224, United States
Twenty volunteers between 21-50 years old will each participate in 16 total sessions, including sessions for: screening, preparation, experiment/drug, immediate follow-ups, a 1-month follow-up and 1 post completion urine collection. On each of five experimental session participants will orally ingest capsules of either a placebo or varying doses of one of 18 different psychoactive compounds.
Subjective drug effects will be examined with methods previously used by this laboratory for characterizing the effects of psychoactive substances from a variety different classes. Volunteers will swallow capsules containing various doses of drugs, complete tasks during the session, and rate effects of the drug and complete questionnaires at the end of each session as described below.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Psychiatric Exclusion Criteria:
One of the following or placebo will be given:
Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis
Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem
Antihistamines: diphenhydramine, chlorpheniramine
Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion
Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine
Other: alcohol, scopolamine, nicotine
Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are "blind" to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects.
Other names: Hallucinogens, Sedatives & anxiolytics, Antihistamines, Stimulants, Opioids, Alcohol, Scopolamine, Nicotine
Time frame: Completed at the end of the experimental session (approximately 8 hours after capsule administration)
Volunteer-completed questionnaire assesses the subjective liking of the drug condition for the session
Time frame: Completed at the end of the experimental session (approximately 8 hours after capsule administration)
This questionnaire has been used in various studies to characterize the profile of subjective and cognitive effects of various types of drugs classified as hallucinogens
Johns Hopkins University
Other
Phase I Study Characterizing Effects of Hallucinogens and Other Drugs on Mood and Performance
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details